Диссертация (1139475), страница 38
Текст из файла (страница 38)
Stereospecificity ina new type of synthetic antituberculous agent // J. Am. Chem. Soc. – 1961. –Vol. 83. – P. 2212-2213.510. Winters, N. Efficacy and safety of World Health Organization group 5 drugsfor multidrug-resistant tuberculosis treatment. / N. Winters, G. Butler-Laporte,D. Menzies. // Eur Respir J. - 2015. - № 46(5).
- 1461-70.511. Wong, S.Y., Lee, J.S., Kwak, H.K., Via, L.E., Boshoff, H.I., Barry, C.E.Mutations in gidB confer low level streptomycin resistance in Mycobacteriumtuberculosis // Antimicrob. Agents Chemother. – 2011. – Vol. 55. – P. 2515 2522.512. WorldHealthOrganization,Globaltuberculosisreport 2017.https://www.who.int/tb/publications/global_report/gtbr2017_executive_summary_ru.pdf?ua=1.513. WorldHealthOrganization,GlobaltuberculosisreportWHO/HTM/TB/2016.13 Geneva, World Health Organization, 2016.2016.253514. World Health Organization.
WHO Global Strategy for Containment ofAntimicrobial Resistance. Geneva, 2001.WHO/CDS/CSR/DRS/2001.2.515. World Health Organization.Anti-tuberculosis drug resistance in the world:fourth global report. - Geneva: World Health Organization, - 2008.516. World Health Organization.Companion handbook to the WHO guidelines forthe programmatic management of drug-resistant tuberculosis. - Geneva: WorldHealth Organization, - 2014. – 448 p.517. World Health Organization.Global tuberculosis control: epidemiology,strategy, financing.
- Geneva: World Health Organization, - 2009.518. Wu S. Adverse events associated with the treatment of multidrug-resistanttuberculosis: a systematic review and meta-analysis / S. Wu, Y. Zhang, F. Sun,M. Chen, L. Zhou, N. Wang, S. Zhan //American Journal of Therapeutics. –2016. – Vol. 23. – № 2. – P. 521–530.519. Xie B.
et al. Pulmonary resection in the treatment of 43 patients with welllocalized, cavitary pulmonary multidrug-resistant tuberculosis in Shanghai.Interactive CardioVascular and Thoracic Surgery 2013; 17: 455–459520. Xin Yu-Ling. Advanced evaluation on surgical treatment of pulmonarytuberculosis // Surgery of tuberculosis. Abstracts Moscow internationalconference. – 1997. – P.
77-78.521. Yang T.W., Park H.O., Jang H.N. et al. Side effects associated with thetreatment of multidrug-resistant tuberculosis at a tuberculosis referral hospitalin South Korea: A retrospective study // Medicine (Baltimore). - 2017; 96(28):P.
7482.522. Yano M., Arai T., Inagaki K., Nomura T. Surgically unsuccessful cases withpulmonary tuberculosis // Kekkaku. – 1997. – Vol. 72. - №1. – P. 35-38.523. Yeager R., Munroe W., Dessau F. Pyrazinamide (Aldinamide) in thetreatment of pulmonary tuberculosis // Am. Rev. Tuberc. - 1952. - Vol. 65.
– P.523–534.524. Yee D. Incidence of serious side effects from first-line antituberculosis drugsamong patients treated for active tuberculosis / D. Yee, C. Valiquette, M.254Pelletier, I. Parisien, I. Rocher, D. Menzies //Am J Respir Crit Care Med. –2003. – Vol. 167. – P. 1472–1477525. Yew W.W. et al. In-vitro activity of quinolones and macrolides againstmycobacteria// J. Antimicrob. Chemother. – 1994. – Vol. 34. – P. 343-351.526.
Zaunbrecher M.A., Sikes R.D., Metchock B., Shinnick T.M., Posey, J.E.OverexpressionacetyltransferaseeisoftheconferschromosomallykanamycinencodedresistanceinaminoglycosideMycobacteriumtuberculosis // Proc. Natl. Acad. Sci. U. S. A. - 2009. - Vol. –106. – P. 20004 20009.527. Zhang S., Chen J., Shi W., Liu W., Zhang W., Zhang Y. Mutations in panDencoding aspartate decarboxylase are associated with pyrazinamide resistancein Mycobacterium tuberculosis // Emerg.
Microbes Infect. - 2013. – Vol. 2. –P. e34.528. Zhang S. Preventive use of a hepatoprotectant against anti-tuberculosisdruginduced liver injury: A randomized controlled trial / S. Zhang, H. Pan, X.Peng, H. Lu, H. Fan, X. Zheng, G. Xu, M. Wang, J. Wang // J GastroenterolHepatol. – 2016. – Vol.
31. – №2. – P. 409–16.529. Zhang Y. et al. The catalase—peroxidase gene and isoniazid resistance ofMycobacterium tuberculosis // Nature. – 1992. – Vol. – 358. – P. 591–593.530. Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis / Y.Zhang, W. W. Yew // Int J Tuberc Lung Dis. – 2009. – T. 13. – № 11. – С.1320-1330.531. Zhang Y.
Mode of action of pyrazinamide: disruption of Mycobacteriumtuberculosis membrane transport and energetics by pyrazinoic acid / Y. Zhang,M. M. Wade, A. Scorpio, H. Zhang, Z. Sun // J Antimicrob Chemother. – 2003.– T. 52. – № 5. – С. 790-795.532. Zhang Y. The magic bullets and tuberculosis drug targets / Y. Zhang // AnnuRev Pharmacol Toxicol. – 2005. – T. 45. – № – С. 529-564.255533. Zhao L.
L. Prevalence and molecular characteristics of drug-resistantMycobacterium tuberculosis in Hunan, China / L. L. Zhao, Y. Chen, Z. N.Chen, H. C. Liu, P. L. Hu, Q. Sun, X. Q. Zhao, Y. Jiang, G. L. Li, Y. H. Tan, K.L. Wan // Antimicrob Agents Chemother. – 2014. – T. 58. – № 6. – С. 3475 3480..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
